Fei Z. Zhou

No. 507, Zheng Min Road
Shanghai, 200433, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 146 publications

Direct Cytosolic Delivery of Amphiphilic Framework Nucleic Acids for RNA Interference.

Direct Cytosolic Delivery of Amphiphilic Framework Nucleic Acids for RNA Interference.

Journal: Angewandte Chemie (International ed. in English)

Published: February 27, 2026

Retraction notice to"Long noncoding RNA CDKN2B-AS1 Interacts with miR-411-3p to regulate ovarian cancer in vitro and in vivo through HIF-1a/VEGF/P38 pathway" [Biochem. Biophys. Res.Commun. 514 (2019) 44-50].

Retraction notice to"Long noncoding RNA CDKN2B-AS1 Interacts with miR-411-3p to regulate ovarian cancer in vitro and in vivo through HIF-1a/VEGF/P38 pathway" [Biochem. Biophys. Res.Commun. 514 (2019) 44-50].

Journal: Biochemical and biophysical research communications

Published: February 20, 2026

Endothelial VEGFR2 insufficiency promotes the transition of lymphatic to hematopoietic transcriptional programs.

Endothelial VEGFR2 insufficiency promotes the transition of lymphatic to hematopoietic transcriptional programs.

Journal: Angiogenesis

Published: January 23, 2026

Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with advanced non-small-cell lung cancer in China.

Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with advanced non-small-cell lung cancer in China.

Journal: Journal of comparative effectiveness research

Published: November 14, 2025

The evolving landscape of bispecific antibodies in the treatment of lung cancer.

The evolving landscape of bispecific antibodies in the treatment of lung cancer.

Journal: Current opinion in oncology

Published: November 12, 2025

Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches.

Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches.

Journal: Nature reviews. Clinical oncology

Published: October 15, 2025

Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058).

Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058).

Journal: Frontiers in pharmacology

Published: August 15, 2025

The pathogenesis and therapeutic management of rare pulmonary sarcomatoid carcinoma: a narrative review.

The pathogenesis and therapeutic management of rare pulmonary sarcomatoid carcinoma: a narrative review.

Journal: Translational lung cancer research

Published: July 31, 2025

Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.

Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.

Journal: Nature communications

Published: July 21, 2025

Bispecific T-cell Engager (CD3 × EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in Third-Generation EGFR-Tyrosine Kinase Inhibitor-Refractory NSCLC.

Bispecific T-cell Engager (CD3 × EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in Third-Generation EGFR-Tyrosine Kinase Inhibitor-Refractory NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: July 04, 2025

GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.

GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 19, 2025

A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC.

A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: May 19, 2025

Showing 1-12 of 146

Last Updated: 09/26/2026